Table 1 Outcomes of randomised trials
Outcome | Number of trials | Number of patients | Percentage with MMF | Percentage with cyclophosphamide | Relative benefit or risk (95% CI) | NNT (95% CI) |
|---|---|---|---|---|---|---|
Efficacy | Â | Â | Â | Â | Â | Â |
   Complete response | 4 | 266 | 36 | 23 | 1.5 (1.1 to 2.1) | 7.6 (4.2 to 43) |
   Complete or partial response | 5 | 306 | 66 | 54 | 1.2 (1.03 to 1.4) | 8.0 (4.3 to 60) |
   Subsequent relapse | 2 | 102 | 27 | 34 | 0.8 (0.4 to 1.4) |  |
Adverse events | Â | Â | Â | Â | Â | NNTp (95% CI) |
   Death | 5 | 306 | 0.7 | 7.8 | 0.2 (0.07 to 0.7) | 14 (8 to 48) |
   Hospital admission | 2 | 220 | 1.7 | 15 | 0.1 (0.04 to 0.5) | 7.4 (4.8 to 16) |
   Adverse event discontinuations | 3 | 246 | 1.6 | 5.6 | 0.3 (0.08 to 1.4) |  |
   All infections | 4 | 280 | 39 | 73 | 0.5 (0.4 to 0.7) | 3.0 (2.3 to 4.4) |
   Serious infections | 4 | 304 | 3.9 | 15 | 0.3 (0.1 to 0.6) | 8.7 (5.5 to 21) |
   Leucopaenia | 3 | 122 | 1.6 | 25 | 0.1 (0.03 to 0.5) | 4.3 (2.9 to 8.3) |
   Amenorrhea | 5 | 312 | 1.9 | 12 | 0.2 (0.08 to 0.6) | 9.5 (6.2 to 20) |
   Hair loss | 3 | 240 | 0.0 | 16 | 0.1 (0.01 to 0.4) | 6.4 (4.4 to 11) |
| Â | Â | Â | Â | Â | Â | NNH (95% CI) |
   Diarrhoea | 4 | 260 | 16 | 4.0 | 4.0 (1.5 to 10) | 8.5 (5.3 to 21) |